Company: FENC
Filing Date: 2025-08-14
Form Type: 10-Q
Source: 0001558370-25-011552
Chunk: 9

Company: FENNEC PHARMACEUTICALS INC.
Filing Date: 2025-08-14
Form: 10-Q
Item: Part I, Item 4C
Chunk 9
---
 to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate. We intend to continue to monitor and upgrade our internal controls as necessary or appropriate for our business but cannot assure that such improvements will be sufficient to provide us with effective internal control over financial reporting.

​

PART II: OTHER INFORMATION

Item 1. Legal Proceedings. 

CIPLA Litigation

On December 1, 2022, we received a letter dated November 30, 2022, notifying us that CIPLA Ltd. and CIPLA USA (“CIPLA”) submitted to the FDA an ANDA (ANDA No. 218028) for a generic version of PEDMARK® (sodium